Financing - June 22, 2022
OnDosis completes a private placement of 75 million SEK
Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen. The private placement enables acceleration of new projects in collaboration with an unnamed license partner as well as the building of the digital platform for the company to develop and introduce closed loop disease […]
Collaboration - May 27, 2021
OnDosis expands collaboration with Tiefenbacher Group
OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new development projects targeting ADHD, rare diseases and transplantation medicine. Last year, the two companies began cooperating on an ADHD treatment that has already received attention in the USA, states the company in a press release. “Whilst our first ADHD project fast approaches final stages […]
Financing - September 15, 2020
OnDosis announces the commitment of a 30 MSEK raise
The commitment from existing owners and DIG Investment follows a signing of a strategic partnership agreement between OnDosis and Tiefenbacher Group. With the partnership and raise, OnDosis will be able to execute the nearterm growth agenda; initially focusing on bringing OnDosis’ ADHD drug/device combination currently in development to the market in the US. This followed […]
Agreement - September 10, 2020
OnDosis enters strategic partnership
Tiefenbacher Group and OnDosis have announced the signing of a co-development agreement for multiple products in the upcoming years. The agreement covers future potential collaboration of products within five disease areas, where individualized dosing, improved patient engagement and patient safety are important to improve outcomes, they state. The first project within ADHD is already initiated […]
